Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Disease
- Therapeutic
- Bacterial Infection
- Antibiotic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 209543
Deformylase is an essential enzyme present in bacteria but absent in human cells, and thus represents a good target for the discovery of inhibitors that can serve as broad spectrum antibacterial agents.
VERSICOR PATENT RIGHTS
1. Title. Methods for Solid-Phase Synthesis of Hydroxylamine Compounds and Derivatives and Combinatorial Libraries Thereof – U.S. Serial No. 08/958,638
2. Title Direct Adsorption Scintillation Assay for Measuring Enzyme Activity and Assaying Biochemical Processes
The Parties are developing deformylase inhibitors as antibacterial agents.
IPSCIO Record ID: 203561
For the research licenses, Licensor grants during the Research Term a worldwide, exclusive, with reserved rights to Licensor, a license, under the Licensor Know-how and Patents as necessary for Licensee to conduct its obligations and tasks under the Research Plan.
For the commercialization license, Licensor grants during the Term of this Agreement a worldwide, exclusive license under the Licensors Know-how and Patents to use, make, have made, market, distribute, promote, offer for sale, sell, export and import Product, including the right to grant sublicenses to Affiliates and Sublicensees.
The oxazolidinone class of antibiotics is a relatively recent addition to the antimicrobial world and have been found to be especially useful in treating infections caused by Gram-positive bacteria.
The patents are for Method For Solid Phase Synthesis of Alcohol Derivatives and Resulting Compositions; and Oxazolidinone Combinatorial Libraries, Compositions and Methods of Preparation.
This application discloses methods for the solid phase synthesis of oxazolidinones; oxazolidinone combinatorial libraries and methods for their synthesis; pharmaceutical compositions comprising bioactive oxazolidinone compounds, including those adapted for oral, topical or parenteral use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect compounds with activity for treatment of disease states such as inflammation, infection, hypertension, CNS disorders and cardiovascular disorders.
TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
This application discloses combinatorial libraries comprising oxazolidinones; methods of preparation of the libraries; biologically active oxazolidinone compositions including compositions for use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect bioactive compounds useful for treatment of disease states such as inflammation, infection, hypertension, central nervous system disorders and cardiovascular disorders.
TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
Biologically active oxazolidinones, libraries and pharmaceutical compositions, and methods of preparation are disclosed, wherein the biologically active oxazolidinones may be used in pharmaceutical applications including use as sedatives, anticonvulsants, muscle relaxants, anti-Parkinson agents, analgesics, antiinflammatories, local anesthetics, muscle contractants, antibiotic, antiviral, antiretroviral, antimalarials, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics and chemotherapy agents, as well as for treatment of cardiovascular diseases, central nervous system diseases, cancer, metabolic disorders, infections and dermatological diseases as well as other biological disorders and infections.
IPSCIO Record ID: 3262
The Licensor is a specialty pharmaceutical company that acquires, develops, markets and sells prescription drugs through our direct sales force and international distributors. We focus on the treatment of central nervous system (CNS) diseases and gastroenterological disorders, which are served by a limited group of physicians such as neurologists and gastroenterologists.
IPSCIO Record ID: 209539
Licensor has developed and owns certain drug discovery technology and intellectual property rights, including but not necessarily limited to chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for biological screening assays and medicinal chemistry.
Licensee desires to utilize Licensor Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of human disease in the area of oncology.
